Author:
El Cheikh J,Massoud R,Abudalle I,Haffar B,Mahfouz R,Kharfan-Dabaja M A,Jisr T,Mougharbel A,Ibrahim A,Bazarbachi A
Publisher
Springer Science and Business Media LLC
Subject
Transplantation,Hematology
Reference15 articles.
1. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002; 359: 2065–2071.
2. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363: 1812–1821.
3. Howell M, Gibb A, Radford J, Linton K . Bendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin. Br J Haematol (e-pub ahead of print 22 July 2016; doi:10.1111/bjh.14257).
4. Zinzani PL, Vitolo U, Viviani S, Corradini P, Motta G, Tani M et al. Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patients. Clin Lymphoma Myeloma Leuk 2015; 15: 404–408.
5. Anastasia A, Carlo-Stella C, Corradini P, Salvi F, Rusconi C, Pulsoni A et al. Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi. Br J Haematol 2014; 166: 140–142.
Cited by
38 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献